Deals News Hubb
Advertisement Banner
  • Home
  • Business Deals
  • Shopping Deals
  • Contact
No Result
View All Result
  • Home
  • Business Deals
  • Shopping Deals
  • Contact
No Result
View All Result
Gourmet News Hubb
No Result
View All Result
Home Business Deals

Moderna, Merck mRNA cancer shot cut relapse or death in melanoma (NYSE:MRK)

admin by admin
April 17, 2023
in Business Deals


Kameleon007/iStock via Getty Images

Merck (NYSE:MRK) and Moderna (NASDAQ:MRNA) presented detailed mid-stage results for a combination therapy containing vaccine maker’s personalized cancer shot mRNA-4157 (V940) and pharma giant’s blockbuster cancer therapy Keytruda at a medical event on Sunday.

The companies said that the novel therapeutic regimen cut the risk of recurrence or death by 44%, leading to a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) compared to Keytruda alone in patients with skin cancer, melanoma.

The Phase 2b KEYNOTE-942 (mRNA-4157-P201) trial involved patients with resected melanoma (stage III/IV) with high risk of recurrence, out of whom 107 received mRNA-4157 plus Keytruda and 50 patients underwent only Keytruda therapy.

22.4% and 40% of patients were shown to have disease recurrence or death in the combination arm and Keytruda-only arm, with a median follow-up of 23 and 24 months, respectively.

The 12-month recurrence-free survival (RFS) rates stood at 83.4% and 77.1%, and 18-month RFS rates reached 78.6% and 62.2% in mRNA-4157 plus Keytruda and Keytruda-only arms, respectively.

The incidence of Grade 3 or worse adverse events was found to be 25% vs. 18% in those in the combination therapy and the monotherapy arms, respectively, with fatigue (60.6%), injection site pain (55.8%) and chills (50.0%) being most common adverse events.

In 2023, Merck (MRK) and Moderna (MRNA) expect to begin a Phase 3 trial for the combination therapy in adjuvant melanoma before expanding studies to additional cancer types, such as non-small cell lung cancer.

The data were part of a presentation at the ongoing American Association for Cancer Research (AACR) Annual Meeting 2023.

Ahead of the readout, Merck (MRK) announced a buyout deal to acquire the immunology-focused biotech Prometheus Biosciences (RXDX) for nearly $11B in cash.

Posting initial results, Merck (MRK) and Moderna (MRNA) said in December KEYNOTE-942 met the primary endpoint of RFS with a statistically significant and clinically meaningful improvement.



Source link

Previous Post

$10 Family Lunch At Sam’s Club?! (Plus $10 Membership and Freebies Tomorrow!!)

Next Post

Sundar Pichai on A.I. being ‘more profound’ than fire

Next Post

Sundar Pichai on A.I. being 'more profound' than fire

Recommended

Saucony Running Shoes as low as $51.82 shipped (Reg. $130!)

4 months ago

BookNook Careers: Online Tutoring Jobs

6 months ago

How to Make It Happen in a Few Steps

4 months ago

Elon Musk says a lithium shortage is holding back Tesla. His solution? Building a lithium refinery in Texas

8 months ago

The Sephora Official Annual Sales Event Calendar in 2022

6 months ago

Goldman Sachs workers laid off in ‘meetings’ they’d been invited to: Report 

5 months ago
Deals-(-White-)

© Deals News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • Business Deals
  • Shopping Deals
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • Business Deals
  • Shopping Deals
  • Contact

© 2022 Deals News Hubb All rights reserved.